Accessing external innovation in drug discovery and development

Bibliography

• Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 2010;9:203–14
   PubMed Web of Science ®Google Scholar
• Scannell JW, Blanckley A, Boldon H, et al. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 2012;11:191–200
   PubMed Web of Science ®Google Scholar
• Khanna I. Drug discovery in pharmaceutical industry: productivity challenges and trends. Drug Discov Today 2012;17:1088–102
   PubMed Web of Science ®Google Scholar
• Melese T, Lin SM, Chang JL, et al. Open innovation networks between academia and industry: an imperative for breakthrough therapies. Nat Med 2009;15:502–7
   PubMed Web of Science ®Google Scholar
• Hunter J. Is open innovation the way forward for big pharma? Nat Rev Drug Discov 2010;9:87–8
   Web of Science ®Google Scholar
• Schuhmacher A, Germann PG, Trill H, et al. Models for open innovation in the pharmaceutical industry. Drug Discov Today 2013;18:1133–7
   PubMed Web of Science ®Google Scholar
• Wang L, Plump A, Ringel M. Racing to define pharmaceutical R&D external innovation models. Drug Discov Today 2014;14:413–19
   Google Scholar
• Giardina GA, Raveglia LF. Creating effective medicinal chemistry collaborations in drug discovery. Future Med Chem 2009;1:3–6
   PubMed Web of Science ®Google Scholar
• Ekins S, Waller CL, Bradley MP, et al. Four disruptive strategies for removing drug discovery bottlenecks. Drug Discov Today 2013;18:265–71
   PubMed Web of Science ®Google Scholar
• Graya JV, Rothb AV, Leibleina MJ. Quality risk in offshore manufacturing: Evidence from the pharmaceutical industry. J Operat Manage 2011;29:737–52
   Web of Science ®Google Scholar
• Festel G. Outsourcing chemical synthesis in the drug discovery process. Drug Discov Today 2011;16:237–43
   PubMed Web of Science ®Google Scholar
• Subramaniam S, Dugar S. Outsourcing drug discovery to India and China: from surviving to thriving. Drug Discov Today 2012;17:1055–8
   PubMed Web of Science ®Google Scholar
• International federation of pharmaceutical manufacturers & associations (IFPMA). The pharmaceutical industry and global health: Facts and Figures. IFPMA 2014
   Google Scholar
• Long G, Works J. Innovation in the biopharmaceutical pipeline: A Multidimensional View. Analysis group 2013
   Google Scholar
• Judd DB. Open innovation in drug discovery research comes of age. Drug Discov Today 2013;18:315–17
   PubMed Web of Science ®Google Scholar
• Rognan D. Chemogenomic approaches to rational drug design. Br J Pharmacol 2007;152:38–52
   PubMed Web of Science ®Google Scholar
• Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008;4:682–90
   PubMed Web of Science ®Google Scholar
• Oprea TI, Tropsha A, Faulon JL, et al. Systems chemical biology. Nat Chem Biol 2007;3:447–50
   PubMed Web of Science ®Google Scholar
• Wild DJ, Ding Y, Sheth AP, et al. Systems chemical biology and the semantic web: what they mean for the future of drug discovery research. Drug Discov Today 2012;17:469–74
   PubMed Web of Science ®Google Scholar
• Ullman F, Boutellier RA. Case study of lean drug discovery: from project driven research to innovation studios and process factories. Nat Rev Drug Discov 2008;13:543–50
   Google Scholar
• Garnier JP. Rebuilding the R&D engine in big pharma. Harvard Bus Rev 2008;86:68–76
   PubMed Web of Science ®Google Scholar
• Owens PK, Raddad E, Miller JW, et al. A decade of innovation in pharmaceutical R&D: the Chorus model. Nat Rev Drug Discov 2015;14:17–28
   PubMed Web of Science ®Google Scholar
• Villoutreix BO, Kuenemann MA, Poyet JL, et al. Drug-like protein-protein interaction modulators: challenges and opportunities for drug discovery and chemical biology. Mol Inform 2014;33:414–37
   PubMed Web of Science ®Google Scholar
• DiMasi JA, Grabowski HG. The cost of biopharmaceutical R&D: Is biotech different? Manage Decis Econ 2007;28:469–79
   Google Scholar
• Muller JC. Small moleccules or biologics? That is the question MedNous. 2013. Available from: http://btobioinnovation.com/small-molecules-or-biologics/
   Google Scholar
• Evaluate Pharma World Preview 2014, Outlook to 2020, Evaluate Pharma. 2014. Available from: http://www.evaluategroup.com/public/Reports/EvaluatePharma-World-Preview-2014.aspx
   Google Scholar
• Alvim-Gaston M, Timothy Grese T, Mahoui A, et al. Open Innovation Drug Discovery (OIDD): a potential path to novel therapeutic chemical space. Curr Top Med Chem 2014;14:294–303
   PubMed Web of Science ®Google Scholar
• Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic targets through human genetics. Nat Rev Drug Discov 2013;12:581–94
   PubMed Web of Science ®Google Scholar
• Yu J, Nag SA, Zhang R. Advances in translational pharmacological investigations in identifying and validating molecular targets of natural product anticancer agents. Curr Cancer Drug Targets 2013;13:596–609
   PubMed Web of Science ®Google Scholar
• Bamrungsap S, Zhao Z, Chen T, et al. Nanotechnology in therapeutics. a focus on nanoparticles as a drug delivery system. Nanomedicine 2012;7(8):1253–71
   PubMed Web of Science ®Google Scholar
• Ming X, Liang B. Bioconjugates for targeted delivery of therapeutic oligonucleotides. Adv Drug Deliv Rev 2015. [Epub ahead of print]
   Web of Science ®Google Scholar
• UCSF Innovation, Technology & Alliances. Available from: http://ita.ucsf.edu/
   Google Scholar
• QB3. Available from: http://www.qb3.org
   Google Scholar
• Centers for Therapeutic Innovation. CTI Updates [ONLINE]. Available from: https://www.pfizercti.com/cti_news/press_releases [Last accessed 10 April 2015]
   Google Scholar
• FierceBiotech. 20 Major pharma-academic alliances in [ONLINE]. 2012. Available from: http://www.fiercebiotech.com/slideshows/20-major-pharma-academic-alliances-2012 [Last accessed 10 April 2015]
   Google Scholar
• The novo nordisk foundation center for protein research. Available from: http://www.cpr.ku.dk/
   Google Scholar
• The novo nordisk foundation center for basic metabolic research. Available from: http://metabol.ku.dk/
   Google Scholar
• The novo nordisk foundation center for biosustainability. Available from: http://www.biosustain.dtu.dk/
   Google Scholar
• Chesbrough H. Open Innovation. The new imperative for creating and profiting from technology. Harvard Business; School Press; Boston, Massachusets, USA; 2003
   Google Scholar
• Sheridan C. Industry continues dabbling with open innovation models. Nat Biotechnol 2011;29:1063–5
   PubMed Web of Science ®Google Scholar
• Wikipedia. List of Crowdsourcing Projects [ONLINE]. Available from: http://en.wikipedia.org/wiki/List_of_crowdsourcing_projects [Last accessed 10 April 2015]
   Google Scholar
• Sage Bionetworks. Available from: http://sagebase.org
   Google Scholar
• Dorsch H, Jurock AE, Schoepe S, et al. Grants4Targets: an open innovation initiative to foster drug discovery collaborations. Nat Rev Drug Discov 2015;14:74–6
   PubMed Web of Science ®Google Scholar
• Innocentive. Available from: http://www.innocentive.com/
   Google Scholar
• Marti-Solano M, Birney E, Bril A, et al. Integrative knowledge management to enhance pharmaceutical R&D. Nat Rev Drug Discov 2014;13:239–40
   PubMed Web of Science ®Google Scholar
• Collaborative Drug Discovery. Available from: https://www.collaborativedrug.com/
   Google Scholar
• Gewin V. Social networking seeks critical mass. Nature 2010;468:993–4
   Google Scholar
• Lilly Clinical Open Innovation. More patient engagement, Please! 50th drug information association annual meeting. [ONLINE]. Available from: http://portal.lillycoi.com/tag/pharma-social-media/ [Last accessed 10 April 2015]
   Google Scholar
• Market Realist. Mergers seem to be a prescription for growth for pharmaceuticals [ONLINE]. Available from: http://marketrealist.com/2014/05/ma-seems-prescription-growth-big-pharma/ [Last accessed 10 April 2015]
   Google Scholar
• Mullard A. Built-to-buy start-ups begin to bloom. Nat Rev Drug Discov 2014;13:161–2
   PubMed Web of Science ®Google Scholar
• Bioworld. GSK, J&J join index ventures’ Asset-Based $199M VC Fund. [ONLINE]. Available from: http://www.bioworld.com/content/gsk-jj-join-index-ventures-asset-based-199m-vc-fund-0 [ [Last accessed 10 April 2015]
   Google Scholar
• Love B. Virtual pharmaceutical R&D: a strategy for the millennium? Pharm Sci Technol Today 1998;1:89–90
   Google Scholar
• Lawrence RN. Alastair devlin discusses the concept of virtual pharma companies. Drug Discov Today 2001;6:508–9
   PubMed Web of Science ®Google Scholar
• Forster SP, Stegmaier J, Spycher R, et al. Virtual pharmaceutical companies: collaborating flexibly in pharmaceutical development. Drug Discov Today 2014;19:348–55
   PubMed Web of Science ®Google Scholar
• Longman R. Flexion exploits big pharma as discovery supplier. In Vivo Bus Med Rep 2010;28:1–4
   Google Scholar
• Silicon Valley Bank. Trends in healthcare investments and exits. 2014. Available from: https://www.svb.com/uploadedFiles/Content/Blogs/Healthcare_Report/healthcare-report-2014-presentation.pdf [Last accessed 10 April 2015]
   Google Scholar